Novo Nordisk’s Wegovy pill approved in US as first oral GLP-1 for weight management
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Subscribe To Our Newsletter & Stay Updated